Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 29, 2024Journal of Bone and Mineral ResearchOpen Access

Goal-Directed Osteoporosis Treatment: ASBMR/BHOF Task Force Position Statement 2024

View Full Paper
Ask AI
Bookmark
Share

Authors

FCFelicia CosmanHelen Hayes HospitalELE. Michael LewieckiCreighton UniversityRichard EastellRichard EastellUniversité Claude Bernard Lyon 1

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cosman et al. (2024) studied this question.

synapsesocial.com/papers/68e5ea28b6db64358757e666https://doi.org/10.1093/jbmr/zjae119
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis2007 · 2,994 citations
  2. 2Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension2024 · 23 citations
  3. 3Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?2014 · 129 citations
  4. 4Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials2019 · 359 citations
  5. 5Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update2020 · 440 citations